Socioeconomic status dependent medical complexities in children with sickle cell disease in Saudi Arabia

Shahida Aziz Khan1,2, Fayza AlSiny3, Ahmad Makki1

  • 1Applied Nutrition Group, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.

Insights

Children with sickle cell disease (SCD) from lower socioeconomic status (SES) families experience more frequent vaso-occlusive crises (VOC) and adverse events. This highlights the impact of socioeconomic disparities on SCD complications.

Area of Science:

  • Pediatrics
  • Hematology
  • Public Health

Background:

  • Socioeconomic status (SES) significantly impacts health outcomes.
  • Sickle cell disease (SCD) presents various complications that may be influenced by socioeconomic factors.

Purpose of the Study:

  • To investigate the association between SES and clinical/hematological parameters in children with SCD in Saudi Arabia.
  • To determine if lower SES correlates with increased disease severity or complications.

Main Methods:

  • A cohort of 65 children (5-16 years) with SCD was classified into four socioeconomic classes based on family income (SAR).
  • Assessment included frequency of vaso-occlusive crisis (VOC), adverse events, and hematological parameters.

Main Results:

  • A higher proportion of children from the lowest SES class (Class 1: <5000 SAR) experienced more frequent VOC and adverse events.
  • The 5-10 year age group showed increased susceptibility to adverse events and VOC.

Conclusions:

  • Lower socioeconomic status is associated with a higher frequency of vaso-occlusive crises and adverse events in children with SCD.
  • Findings suggest socioeconomic disparities modify clinical outcomes in pediatric SCD.
  • Further large-scale studies are recommended to confirm these associations.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
161
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
182
Multiple Allele Traits01:49

Multiple Allele Traits

The Concept of Multiple Allelism
37.7K
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
121
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
141
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
444